<unk> , sold under the brand name Viltepso, is a medication used for the treatment of Duchenne muscular dystrophy (DMD).<unk>  is a Morpholino antisense oligonucleotide. The most common side effects include upper respiratory tract infection, injection site reaction, cough, and pyrexia (fever).<unk>  was approved for medical use in the United States in August 2020. After golodirsen was approved in December 2019,<unk>  is the second approved targeted treatment for people with this type of mutation in the United States. Approximately 8% of people with DMD have a mutation that is amenable to exon 53 skipping.
Viltolarsen
Golodirsen
Oleandrin
Tolevamer
Ketotifen
Penmesterol
Androstanolone enanthate
Eluxadoline